EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma

Fei Yang, Yajing Qu, Xiongfang Guo, Ling Li, Sucheng Tan, Xiang Li, Guibing Ren, Lin Ma, Da-Wei Zhao

Advances in Radiation Oncology · 2026-11 · 11 (11) · 102129

DOI: 10.1016/j.adro.2026.102129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Radiation Oncology, 2026-11. Verfasst von Fei Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianjin Science and Technology Program, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

For locoregionally advanced hypopharyngeal carcinoma (LAHPC), organ preservation via induction chemotherapy followed by concurrent chemoradiotherapy (IC-CCRT) is a key strategy, yet robust data from homogeneous cohorts treated with modern radiation therapy are scarce. This prospective study evaluated the efficacy and safety of IC-CCRT in a contemporary LAHPC cohort. Methods and Materials: From January 2015 to December 2021, 259 patients with LAHPC receiving curative-intent IC-CCRT with intensity-modulated radiation therapy were enrolled. Endpoints included survival with functional larynx (SFL), overall survival, progression-free survival, and disease control measures.

Results

The 5-year rates for SFL, overall survival, progression-free survival, local failure-free survival, locoregional failure-free survival, and distant metastasis-free survival (DMFS) were 49.9%, 51.5%, 43.3%, 50.2%, 48.6%, and 46.4%, respectively. Outcomes declined sharply with advancing American Joint Committee on Cancer (AJCC) stage. The 5-year SFL was 89.0% for stage III, 47.0% for stage IVA (hazard ratio [HR] 4.02; 95% CI, 1.66-9.77; P = .002), and 31.7% for stage IVB (HR 2.77; 95% CI, 1.01-7.58; P = .048). T4b classification independently predicted the poorest outcomes, with a 5-year SFL of 25.2% versus 69.9% for T1-3 tumors (HR 3.23; 95% CI, 1.70-6.12; P < .001). AJCC stage and T classification, but not N stage, remained independent prognostic factors across all endpoints. Age was also an independent prognostic factor. Based on these factors, a prognostic nomogram was developed, demonstrating good discrimination (C-index 0.696) and calibration, with decision curve analysis confirming its clinical utility. Grade 3 to 4 hematologic toxicity occurred in 13.9% of patients. Functional impairments were common, including hoarseness (42.1%) and dysphagia (23.2%), with 14.3% requiring feeding tube dependence.

Conclusions

IC-CCRT provides meaningful survival and larynx preservation in LAHPC, but efficacy is highly dependent on AJCC stage and T classification. Patients with T4b tumors have particularly poor outcomes. The developed nomogram offers a practical tool for individual outcome prediction. Treatment should be individualized, balancing survival benefits against significant treatment-related toxicities.

Autor:innen und Institutionen

  • Department of Ultrasound, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China.
  • Department of Oncology, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China.
  • Department of Radiology, Hospital of the Chinese People's Armed Police Force Xinjiang Production and Construction Corps Headquarters, Xinjiang, China.
  • Department of Radiation Oncology, First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Department of Radiation Oncology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Resea…

Förderung

  • Tianjin Science and Technology Program
  • National Natural Science Foundation of China

Zitieren

APA

Yang, F., Qu, Y., Guo, X., Li, L., Tan, S., Li, X., Ren, G., Ma, L., & Zhao, D. W. (2026). Efficacy and Safety of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma. Advances in Radiation Oncology, 11(11), 102129. https://doi.org/10.1016/j.adro.2026.102129

Vancouver

Yang F, Qu Y, Guo X, Li L, Tan S, Li X, et al. Efficacy and Safety of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma. Advances in Radiation Oncology. 2026;11(11):102129. doi:10.1016/j.adro.2026.102129

BibTeX
@article{Yang2026,
  author = {Yang, Fei and Qu, Yajing and Guo, Xiongfang and Li, Ling and Tan, Sucheng and Li, Xiang and Ren, Guibing and Ma, Lin and Zhao, Da-Wei},
  title = {Efficacy and Safety of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma},
  journal = {Advances in Radiation Oncology},
  year = {2026},
  volume = {11},
  number = {11},
  pages = {102129},
  doi = {10.1016/j.adro.2026.102129}
}
Kostenlos starten →